Amy Burroughs

Ms. Burroughs joined the Tenaya Board of Directors in 2022 with more than 20 years of experience in the healthcare and life science industries, with a focus on drug development and commercial planning. She currently serves as President & Chief Executive Officer of Cleave Therapeutics, a clinical stage company focused on valosin-containing protein (VCP) as a novel target in protein homeostasis and cellular stress pathways for therapeutic use in cancer and neurodegenerative diseases. Before joining Cleave, Ms. Burroughs served as Executive in Residence at 5AM Ventures, and as a senior advisor to Crinetics Pharmaceuticals, a 5AM portfolio company. Prior to that she founded the Ventral Group, a strategic life sciences consulting and investor advisory firm for high-growth healthcare companies. Earlier in her career, Ms. Burroughs served as Chief Commercial Officer and head of business development of APT Pharmaceuticals and Commercial Team Leader at Genentech, managing strategy and communications while contributing to the successful launches of Xolair®, Raptiva®, Rituxan® RA and Lucentis®. She began her career in industry with Procter & Gamble, where she was a key contributor to the launch of Aleve®.

Ms. Burroughs earned a Bachelor of Arts in computer science and a minor in economics from Dartmouth College, and an MBA from Harvard Business School. Ms. Burroughs sits on the board of DiaMedica Therapeutics.